CD38 and Miyoshi myopathy: The clinical success of CD38 monoclonal antibodies in MM has stimulated the development of cytotoxic T-cell-based therapeutics, such as CD38 chimeric antigen receptor (CAR) T cells and CD38 (bispecific T-cell engager) BiTE antibodies.